Purchase this article with an account.
Linda Rose, Sean Rivera, Julia Byrd; The use of Sub-Tenon Ranibizumab to Control Pterygium Recurrences. Invest. Ophthalmol. Vis. Sci. 2012;53(14):6821.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate safety, tolerability, and efficacy of sub-tenon Ranibizumab in patients with early pterygium recurrences
In this prospective, open-label pilot study, four subjects with recurrent pterygium were given 0.5mg/0.05ml of sub-tenon Ranibizumab monthly for a total of 3 injections. Patients were followed for 6-12 months after injection. Slit lamp photographs of the lesions were analyzed quantitatively with Photoshop CS5 using the "Magic Wand" tool to define the extent of vascularity within a recurrence, which was reported in pixels. Safety parameters, including subjective reports of symptoms as well as objective examination of the ocular surface were assessed at monthly intervals. Objective parameters included visual acuity, intraocular pressure, Schirmer's test, tear break up time, and presence of punctate erosions.
The mean age of enrolled subjects was 44 years (range: 25-59 years). All four patients tolerated the injections well. Quantitative image results showed an average of 53% reduction of pixels (range: 12-91%) 2 months after Ranibizumab injections were initiated. Long-term effects of the injections were assessed up to 9 months after injection initiation, and showed an average of 50% reduction of pixels (range 14-88%). There were no changes in any of the subjective or objective safety criteria in any subject.
Data from this pilot study suggest that sub-tenon injection of Ranibizumab is well-tolerated and safe. Efficacy of the drug was evident in measurable reduction of lesion vascularity. Longer follow up and larger studies are needed to validate if the drug will be clinically useful to manage early pterygium recurrences.
Image 1: Day 0
Image 2: 5 Months S/P Ranibizumab 0.5mg/0.05ml Sub-tenon
This PDF is available to Subscribers Only